Unveiling the Potential of Zenocutuzumab: A Breakthrough in NSCLC and Pancreatic Adenocarcinoma Treatment.
Zenocutuzumab-zbco, a novel bispecific antibody targeting HER2 and HER3, has demonstrated promising efficacy in non-small cell lung cancer (NSCLC) and pancreatic adenocarcinoma.
APA
Sanan Rasheed Mbbs, Umer Farooq Mbbs, et al. (2025). Unveiling the Potential of Zenocutuzumab: A Breakthrough in NSCLC and Pancreatic Adenocarcinoma Treatment.. Oncology (Williston Park, N.Y.), null(7), 298-300. https://doi.org/10.46883/2025.25921048
MLA
Sanan Rasheed Mbbs, et al.. "Unveiling the Potential of Zenocutuzumab: A Breakthrough in NSCLC and Pancreatic Adenocarcinoma Treatment.." Oncology (Williston Park, N.Y.), vol. null, no. 7, 2025, pp. 298-300.
PMID
40834284
Abstract
Zenocutuzumab-zbco, a novel bispecific antibody targeting HER2 and HER3, has demonstrated promising efficacy in non-small cell lung cancer (NSCLC) and pancreatic adenocarcinoma. In early-phase clinical trials, it has shown an objective response rate of approximately 34% in HER2-amplified NSCLC and a disease control rate exceeding 70% in pancreatic adenocarcinoma with NRG1 fusions. By disrupting HER3-driven oncogenic signaling, zenocutuzumab effectively inhibits tumor proliferation and enhances therapeutic outcomes. Its safety profile remains favorable, with most adverse effects being mild to moderate. This editorial explores the clinical potential of zenocutuzumab in reshaping treatment strategies for NSCLC and pancreatic adenocarcinoma.
MeSH Terms
Humans; Pancreatic Neoplasms; Lung Neoplasms; Antibodies, Monoclonal, Humanized; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma; Erb-b2 Receptor Tyrosine Kinases; Adenocarcinoma of Lung; Receptor, ErbB-3